Клиентская стратегия банков в работе с корпоративным сегментом бизнеса

Данная статья раскрывает информацию о корпоративном сегменте банковской деятельности, способах привлечения и обслуживания юридических лиц. Также в данной статье находится отражение понятию «кредитный портфель для корпоративных клиентов» и особенностям клиентской стратегии коммерческих банков в формировании партнерских отношений в корпоративном бизнесе

Nanosized iron-substituted hydroxyapatites

© 2020 Institute of Physics Publishing. All rights reserved. Introduction of iron ions into hydroxyapatites imparts some useful properties to ceramic materials. We created a porous ceramic material from nanosized iron-substituted HA and studied its physico-chemical and biological properties. It is shown that all the iron ions introduced in the course of synthesis enter into the composition of HA and are characterized by the oxidation state +3. The size of crystals after thermal treatment at 9000 C does not exceed 100 nm, the crystals' shape is close to a sphere. Porous materials from nanosized iron-substituted hydroxyapatites support adhesion and growth of anchorage-dependent cells of mammals

ИННОВАЦИОННОЕ СОТРУДНИЧЕСТВО СТРАН БРИКС

The article is devoted to the development of innovative cooperation between the BRICS, mostly between the Russia and the other members of this alliance. Here we will consider what projects at the moment are related to high technology and research in the scientific sphere, the prospects for further development of cooperation in the high-tech sphere between the BRICS.Статья посвящена развитию инновационного сотрудничества между странами БРИКС, а именно между Российской Федерацией и остальными участниками данного альянса. В статье рассматриваютя проекты, связанные с высокими технологиями и исследованиями в научной сфере. А также перспективы дальнейшего развития сотрудничества в высокотехнологичной сфере между странами БРИКС

Problems and prospects of gene therapy against HIV

Possibilities for the application of gene therapy based on insertion of transgenes into a patient's cells in order to express anti-HIV agents interfering with the virus life cycle analogously to highly active antiretroviral therapy (HAART) were reviewed. Anti-HIV agents based on various types of RNA (ribozymes, antisense RNA, RNA aptamers, RNA decoys, small interfering RNA) and protein agents such as RevM10, intracellular antibodies, and intrakines were described. Results of the first clinical trials showed that one of the principal problems of gene therapy is the maintenance in modified cells of the required level of anti-HIV activity. Several gene-therapy strategies for suppressing expression of chemokine co-receptor CCR5 are known; however, the activity of agents integrated in the anti-CCR5 genome decayed over time (gene silencing). Special attention was paid to the development of a treatment method for HIV-infected cells that used tre-recombinases. Preliminary experiments showed that the use of these drugs led to excision of the integrated HIV proviral DNAfrom the genome in cell lines and mice. This was a promising way to destroy latent virus reservoirs and eradicate the virus from the body. It was concluded that gene therapy will become the most important theme of long-term scientific pharmaceutical developments because it could potentially provide effective treatment or even complete cure of HIV-infection after a single administration. © 2014 Springer Science+Business Media New York

Problems and prospects of gene therapy against HIV

Possibilities for the application of gene therapy based on insertion of transgenes into a patient's cells in order to express anti-HIV agents interfering with the virus life cycle analogously to highly active antiretroviral therapy (HAART) were reviewed. Anti-HIV agents based on various types of RNA (ribozymes, antisense RNA, RNA aptamers, RNA decoys, small interfering RNA) and protein agents such as RevM10, intracellular antibodies, and intrakines were described. Results of the first clinical trials showed that one of the principal problems of gene therapy is the maintenance in modified cells of the required level of anti-HIV activity. Several gene-therapy strategies for suppressing expression of chemokine co-receptor CCR5 are known; however, the activity of agents integrated in the anti-CCR5 genome decayed over time (gene silencing). Special attention was paid to the development of a treatment method for HIV-infected cells that used tre-recombinases. Preliminary experiments showed that the use of these drugs led to excision of the integrated HIV proviral DNAfrom the genome in cell lines and mice. This was a promising way to destroy latent virus reservoirs and eradicate the virus from the body. It was concluded that gene therapy will become the most important theme of long-term scientific pharmaceutical developments because it could potentially provide effective treatment or even complete cure of HIV-infection after a single administration. © 2014 Springer Science+Business Media New York